Anticoagulant Market- by Drug Class, (NOACs, Eliquis, Bevyxxa, Savaysa & Lixiana, Heparins & LMWH, Vitamin K Antagonists and other anticoagulant drugs); by Route of Administration (Oral anticoagulants and Injectable Anticoagulants); by Application (Atrial Fibrillation & Heart Attack, Stroke, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Others); by Distribution Channel ( Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others) and by Region - Global Forecasts 2021 to 2027

The Global Anticoagulants Market was valued at USD 28.8 Bn in 2020 and is expected to reach USD 41.89 Bn by 2027 growing at a CAGR of 7.8% during the forecast period (2021-2027).

In this era, a number of critical and serious diseases have shown increasing prevalence globally. One of the most prevalent disease is cardiovascular diseases (CVDs) which is caused due to the modern changes in the lifestyle globally. CVDs includes a group of disorder of heart and blood vessels that result in severe conditions like coronary heart disease, peripheral arterial disease, cerebrovascular disease, congenital heart disease, rheumatic heart disease, pulmonary embolism and deep vein thrombosis. Anticoagulant, commonly known as blood thinners are used in these diseases to help reduce/prevent the coagulation of blood, prolonging the blood clotting time. According to WHO, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke. Therefore, with the increasing cases of CVDs has resulted in increasing demand for more effective anticoagulants.

Rising number of surgical cases is another prominent factor driving the growth of anticoagulants. Surgery involves the risk of forming blood clots. This is because, the patient lies in the same position for a long-time during surgery, and for hours or days during his/her recovery period. As, lying in the same position leads to the formation of blood clots, the prevention of clots has become an essential part of perioperative surgical care. Therefore, increasing number of surgeries worldwide is leading to rise in the demand of Anticoagulants. For instance, the Center for Diseases Control and Prevention states that every year there are nearly 46.5 million procedures of surgeries performed in the U.S.

Anticoagulants Market

Furthermore, increasing aging population in several nations such as Japan, Singapore is also a key driver for the global anticoagulants market. Older adults are more likely to have conditions such as venous thromboembolism, atrial fibrillation, and knee and hip replacement surgeries and thus have a higher chance of developing blood clots, which in turn increases the risk of heart attacks and strokes. According to world bank, in 2020, an estimated 28.397% of the total population in Japan is older than 65, and is expected to rise to 40% by 2060. Thereby, blood thinners such as Xarelto is commonly prescribed to elders for treating and reducing the risk of blood clots.

The Global Anticoagulant Market Segmentation:

By Drug Class

  • NOACs
  • Eliquis
  • Bevyxxa
  • Savaysa & Lixiana
  • Heparins & LMWH
  • Vitamin K Antagonists
  • Other Anticoagulant Drugs

By Route of Administration

  • Oral Anticoagulants
  • Injectable Anticoagulants

By Application

  • Atrial Fibrillation & Heart Attack
  • Stroke
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Based on drug class, The NOACs segment is the dominant segment in the anticoagulants market and is expected to show high growth rate in the coming years.

On the basis of drug class, the Global Anticoagulant Market is segmented as NOACs, Eliquis, Bevyxxa, Savaysa & Lixiana, Heparins & LMWH, Vitamin K Antagonists and other anticoagulant drugs. The NOACs segment is the dominant segment in the anticoagulants market and is expected to show high growth rate in the coming years. This is due to rising adoption of NOACs in the developing countries and increasing use of NOACs over warfarin. In addition, NOACs drugs, such as betrixaban, rivaroxaban, apixaban, dabigatran and edoxaban are used in the treatment and prevention of atrial fibrillation/myocardial infarction, pulmonary embolism, deep vein thrombosis (DVT). Moreover, NOACs provides several benefits over warfarin, such as no dietary restriction, rapid onset action, predictable pharmacokinetic action, lesser interaction with drugs and food, shorter half-life. These factors are driving the demand for NOAC’s in the global anticoagulants market.

Based on application, the pulmonary embolism (PE) is expected to witness a high growth rate during the forecast period.

On the basis of application, the Global Anticoagulant Market is segmented as Atrial Fibrillation & Heart Attack, Stroke, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE) and Others. Among these, the pulmonary embolism (PE) is expected to witness a high growth rate due to the rising cases of PE globally. Pulmonary Embolism is a life threating condition which sometimes subsequently lead to another serious condition such as deep vein thrombosis (DVT). Moreover, the rising prevalence of PE because of other contributing factors such as cancer, heart diseases and obesity are further expected to drive the growth of anticoagulant market as it helps in the formation of blood clots. However, the atrial fibrillation & heart attack segment is held a significant share in the anticoagulant market, owing to the rising use of anticoagulants in treatment of these conditions. According to the National Center for Biotechnology Information (NCBI), if untreated, acute PE is associated with a significant mortality rate accounting to 30% approximately. Owing to this, there is a high need for treatment of PE, which is further expected to increase the demand of anticoagulants.

Based on region, North America accounted for the largest share in the Global Anticoagulant Market

On the basis of region, Global Anticoagulant Market is segmented as North America, Latin America, Europe, Asia Pacific and Middle East & Africa. Among these, North America accounted for the largest share in 2020, owing to the rising awareness about therapeutic applications of anticoagulants in disease management and the growing obesity rate in the region. Moreover, the U.S. is found to have the highest obesity rate globally which is also positively driving the market in this region. According to Centers of Disease Control and Prevention (CDC), the US obesity prevalence was 42.4% in 2017 – 2018. From 1999–2018, US obesity rate increased from 30.5% to 42.4%. During the same time, the prevalence of severe obesity increased from 4.7% to 9.2%. Moreover, given the direct correlation between obesity and heart diseases, the demand of anticoagulants is high in the U.S., and is expected to witness a high growth rate during the forecast period.

Company Profiles and Competitive Intelligence

The key players operating in the Market are:

  • Aspen Holdings
  • Bayer AG
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co., Ltd.
  • GlaxoSmithKline plc.
  • Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
  • Portola Pharmaceuticals, Inc.
  • Pfizer Inc
  • Sanofi
  • Abbott Laboratories
  • Baxter International Inc.
  • Astrazeneca plc
  • BioVascular Inc.
  • Eli Lilly and Company

The report also provides in-depth analysis of Global Anticoagulant Market dynamics such as drivers and restraints.

Drivers

  • Increasing prevalence of cardiovascular diseases and venous thromboembolism (VTE)
  • Rising geriatric population
  • Increase in the prevalence of obesity

Restraints

  • High price of NOACs
  • Stringent regulations set by various governments
  • Risk of side-effects and complications associated with the usage of oral anticoagulants

The report also provides in-depth analysis of key trends in Global Anticoagulant Market

  • The on-going Covid-19 pandemic has increased the rate of heart attacks globally. A study on Case Rates, Treatment Approaches, and Outcomes in Acute Myocardial Infarction during the Coronavirus Disease 2019 Pandemic published in August 2020 in JAMA Cardiology showed 15,244 hospitalizations in U.S. due to COVID-19 involves 14,724 patients with acute myocardial infarction (AMI). This has resulted in creating a high demand for anticoagulant.

The report also provides in-depth analysis of recent news developments and investments.

  • In October 2019, The Janssen Pharmaceutical Companies of Johnson & Johnson made an announcement that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban). This will help in the prevention of venous thromboembolism (VTE), in acutely ill hospitalized patients who are at a risk for thromboembolic complications but not at high risk of bleeding.
  • In February 2019, Blackstone Life Sciences, a private investment firm, in partnership with Novartis, launched Anthos Therapeutics with a $250 million investment. The compound has the potential to prevent a range of cardiovascular disorders involved in blood clotting.

The unique insight provided by this report also includes the following:

  • In-depth value chain analysis
  • Opportunity mapping
  • Sector snapshot
  • Key Players Positioning Matrix
  • Regulatory scenario
  • Strategies Adopted-Benchmarking Heat Map
  • Market trends
  • Covid-19 impact analysis
  • Product comparison
  • Pre & Post COVID 19 impacts on the Global Anticoagulant Market
  • Competitive Landscape

Frequently Asked Questions (FAQs)

A few key players in the Collaborative Robot Market industry include ABB Group; DENSO Robotics; EPSON Robots; Energid Technologies Corporation; F&P Robotics AG; Fanuc Corporation; KUKA AG; MRK-Systeme GmbH; Precise Automation, Inc.; Rethink Robotics, Inc. among many others.

In the base year 2020, the North American region accounted for the largest share in the Collaborative Robot Market.

The Collaborative Robot Market is estimated to grow at a compound annual growth rate (CAGR) of 41.8% during 2021-2027.

The Global Collaborative Robot Market was valued at USD 725.6 million in 2020, and it is expected to reach USD 11,684.8 million by 2027

The Global Anticoagulant Market was valued at USD 28.8 Bn in 2020 and is expected to reach USD 41.89 Bn by 2027.

The Global Anticoagulant Market is estimated to grow at a compound annual growth rate (CAGR) of 7.8 % during 2020-2027

In the base year 2020, North America accounted for the largest share in the Global Anticoagulant Market.

A few key players in this market are Aspen Holdings, Bayer AG, Boehringer Ingelheim Pharma GmbH & Co. KG, Bristol-Myers Squibb Company, Daiichi Sankyo Co., Ltd., GlaxoSmithKline plc., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Portola Pharmaceuticals, Inc., Pfizer Inc, Sanofi among many others.

Related Reports

Need specific market information ?

Ask for free product review call with the author

Share your specific research requirements for a customized report

Request for due diligence and consumer centric studies

Request for study updates, segment specific and country level reports

  • Section 1: Introduction
    • Engagement Objective
    • Scope of the Study: Segmentation 
    • Timeframe, Currency and Limitations
  • Section 2: Research Methodology
    • 3P Research Approach
    • Market Sizing Approach
    • Data Sources
    • Primary Research Coverage
  • Section 3: Executive Summary
    • Global Anticoagulant Market Summary
    • Market Snapshot
    • Country Snapshot
  • Section 4: Premium Insights
    • Key Trend Analysis
    • Major Investment Scenario
    • New revenue Pockets
    • Pain Point Analysis
    • Price Trend Analysis
    • Strategies Adopted-Benchmarking Heat Map
    • Business Recommendations
      • Opportunity Mapping
    • PESTEL Analysis
    • Market Positioning Matrix
  • Section 5: Market Overview & Competitive Landscape
    • Competitive Landscape
    • Investment Scenario by key Players
    • Key Player Overview
    • Product comparison
    • Competitive Benchmarking
    • Player Wise Geographic Presence
    • Player Wise Target Customer Segment
    • Recent News
      • Product Launches & upgrades
      • R&D / Innovation
      • Merger & Acquisition
      • JV & Partnership
      • Recognition and others
  • Section 6: Market Size and Share Analysis
    • Market Size & Historic Growth
    • Market Size by Player Category
    • Market Size by Drug Class
      • NOACs
      • Eliquis
      • Bevyxxa
      • Savaysa & Lixiana
      • Heparins & LMWH
      • Vitamin K Antagonists
      • Other Anticoagulant Drugs
    • Market Size by Route of Administration
      • Oral Anticoagulants
      • Injectable Anticoagulants
    • Market Size by Application
      • Atrial Fibrillation & Heart Attack
      • Stroke
      • Deep Vein Thrombosis (DVT)
      • Pulmonary Embolism (PE)
      • Others
    • Market Size by Distribution Channel
    • Section 7: Market Dynamics
    • DROC Impact Analysis
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Section 8: Future Forecast & Impact of COVID-19
    • Key Drivers & Anticipated Revival Period
    • Key Trends Analysis
    • Impact on End user Industry
    • Opportunity Analysis
    • Pre & Post COVID 19 impact
    • End-Use Specific COVID-19 Impact
    • Key Factor Analysis
  • Section 9: Regional Market Size and Share Analysis
    • North America
      • Market Overview and Analysis
      • Key Country Analysis
        • US
        • Canada
    • Europe
      • Market Overview and Analysis
      • Key Country Analysis
        • Germany
        • UK
        • France
        • Italy
        • Spain
        • Rest of Europe
    • Asia Pacific
      • Market Overview and Analysis
      • Key Country Analysis
        • China
        • India
        • Japan
        • South Korea
        • Rest Of APAC
    • Latin America
      • Market Overview and Analysis
      • Key Country Analysis
        • Brazil
        • Argentina
        • Rest of LATAM
    • Middle East & Africa
      • Market Overview and Analysis
      • Key Country Analysis
        • GCC
        • Rest of MEA
  • Section 10: Company Profile
      1. Aspen Holdings
      2. Bayer AG
      3. Boehringer Ingelheim Pharma GmbH & Co. KG
      4. Bristol-Myers Squibb Company
      5. Daiichi Sankyo Co., Ltd.
      6. GlaxoSmithKline plc.
      7. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
      8. Portola Pharmaceuticals, Inc.
      9. Pfizer Inc
      10. Sanofi

Choose License

License Type
Ask for Customization

Why Choose AllTheResearch?

  • Monthly market updates for 6 months
  • Online access of reports
  • Options to buy sections of report
  • Critically analysed research on Quadrant Positioning of your company.
  • Syndicated report along with a supplementary report with objective-based study
  • Get profiled in the reports.Expanding your visibility across our network of readers and viewers
  • We provide local market data in local language on request
  • A complementary co-branded white paper
  • Flat consulting fee based exclusive studies. Consult at the price of syndicate
  • Access to expert team for free transaction advisory service.
Speak to Analyst

Quick Inquiry

Follow Us

Choose License

License Type
Ask for Customization